According to filings with the U.S. Securities and Exchange Commission, Ascribe Bioscience Inc. is raising up to $15,272,656.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Ascribe Bioscience Inc.
Ascribe Bioscience was founded in 2017 based on discoveries at the Boyce Thompson Institute at Cornell University. We are a team of creative, motivated plant scientists, chemists, agronomists, and business professionals. Our mission is to make agriculture better for people and the environment by developing natural crop protection using small molecules from the soil microbiome to provide farmers with reliable, affordable, and sustainable solutions.

To learn more about Ascribe Bioscience Inc., visit https://ascribebio.com/
Ascribe Bioscience Inc. Linkedin Page: https://www.linkedin.com/company/ascribe-bioscience/

Contact:
Jay Farmer, Chief Executive Officer
607-703-9083
https://www.linkedin.com/in/jay-farmer-88b92335/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.